Collegium Pharmaceutical, Inc. Marketing and Advertising Expense
Collegium Pharmaceutical, Inc. (COLL) reported Marketing and Advertising Expense of $27.78 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:MarketingAndAdvertisingExpense · last filed 2026-02-26
- Collegium Pharmaceutical, Inc. marketing and advertising expense for the quarter ending 2018-12-31 was $4.26M, a 102.62% increase year-over-year.
- Collegium Pharmaceutical, Inc. marketing and advertising expense for the quarter ending 2018-09-30 was $4.95M, a 99.04% increase year-over-year.
- Collegium Pharmaceutical, Inc. marketing and advertising expense for the quarter ending 2018-06-30 was $5.72M, a 122.83% increase year-over-year.
- Collegium Pharmaceutical, Inc. marketing and advertising expense for the quarter ending 2018-03-31 was $2.56M, a 33.63% decline year-over-year.
- Collegium Pharmaceutical, Inc. marketing and advertising expense for fiscal 2025 was $27.78M, a 160.52% increase from fiscal 2024.
- Collegium Pharmaceutical, Inc. marketing and advertising expense for fiscal 2024 was $10.66M, a 43.98% increase from fiscal 2023.
- Collegium Pharmaceutical, Inc. marketing and advertising expense for fiscal 2023 was $7.41M.
- Collegium Pharmaceutical, Inc. marketing and advertising expense for fiscal 2018 was $17.50M, a 58.79% increase from fiscal 2017.
| Period end | Marketing and Advertising Expense 3 month | Marketing and Advertising Expense 3 month as first filed | Marketing and Advertising Expense 6 month | Marketing and Advertising Expense 6 month as first filed | Marketing and Advertising Expense 9 month | Marketing and Advertising Expense 9 month as first filed | Marketing and Advertising Expense 12 month |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | $27.78M 10-K · filed 2026-02-26 | ||||||
| 2024-12-31 | $10.66M 10-K · filed 2026-02-26 | ||||||
| 2023-12-31 | $7.41M 10-K · filed 2026-02-26 | ||||||
| 2018-12-31 | $4.26M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $9.21M derived: sum of 2 quarters · filed 2019-02-27 | $14.94M derived: sum of 3 quarters · filed 2019-02-27 | $17.50M 10-K · filed 2019-02-27 | |||
| 2018-09-30 | $4.95M 10-Q · filed 2018-11-08 | $10.67M derived: sum of 2 quarters · filed 2018-11-08 | $13.24M 10-Q · filed 2018-11-08 | $15.34M derived: sum of 4 quarters · filed 2019-02-27 | |||
| 2018-06-30 | $5.72M 10-Q · filed 2018-08-08 | $8.28M 10-Q · filed 2018-08-08 | $10.38M derived: sum of 3 quarters · filed 2019-02-27 | $12.87M derived: sum of 4 quarters · filed 2019-02-27 | |||
| 2018-03-31 | $2.56M 10-Q · filed 2018-05-09 | $4.67M derived: sum of 2 quarters · filed 2019-02-27 | $7.15M derived: sum of 3 quarters · filed 2019-02-27 | $9.72M derived: sum of 4 quarters · filed 2019-02-27 | |||
| 2017-12-31 | $2.10M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $4.59M derived: sum of 2 quarters · filed 2019-02-27 | $7.16M derived: sum of 3 quarters · filed 2019-02-27 | $11.02M 10-K · filed 2019-02-27 | |||
| 2017-09-30 | $2.49M 10-Q · filed 2018-11-08 | $5.06M derived: sum of 2 quarters · filed 2018-11-08 | $8.92M 10-Q · filed 2018-11-08 | $14.75M derived: sum of 4 quarters · filed 2019-02-27 | |||
| 2017-06-30 | $2.57M 10-Q · filed 2018-08-08 | $6.43M 10-Q · filed 2018-08-08 | $12.26M derived: sum of 3 quarters · filed 2019-02-27 | $15.75M derived: sum of 4 quarters · filed 2019-02-27 | |||
| 2017-03-31 | $3.86M 10-Q · filed 2018-05-09 | $9.70M derived: sum of 2 quarters · filed 2019-02-27 | $13.18M derived: sum of 3 quarters · filed 2019-02-27 | $17.86M derived: sum of 4 quarters · filed 2019-02-27 | |||
| 2016-12-31 | $5.84M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $9.32M derived: sum of 2 quarters · filed 2019-02-27 | $14.00M derived: sum of 3 quarters · filed 2019-02-27 | $16.33M 10-K · filed 2019-02-27 | |||
| 2016-09-30 | $3.49M 10-Q · filed 2017-11-08 | $3.49B 10-Q · filed 2016-11-10 | $8.17M derived: sum of 2 quarters · filed 2017-11-08 | $10.49M 10-Q · filed 2017-11-08 | $10.49B 10-Q · filed 2016-11-10 | ||
| 2016-06-30 | $4.68M 10-Q · filed 2017-08-09 | $4.68B 10-Q · filed 2016-08-11 | $7.01M 10-Q · filed 2017-08-09 | $7.01B 10-Q · filed 2016-08-11 | |||
| 2016-03-31 | $2.33M 10-Q · filed 2017-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |